Journals / Düzce Tıp Fakültesi Dergisi / 2022 / Cilt: 24 - Sayı: Special Issue

Oral Agents for Ovulation Induction

Ovulasyon İndüksiyonunda Oral Ajanlar

Pages
90–96
Publication Date
2022-10-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Similarly, when inositol is used alone, it does not increase the pregnancy rate.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Infertility due to ovulation disorders is 25% of all infertility causes.
📊
Key Findings & Data:The most common cause of ovulation disorders is patients with normogonadatropic normogonadism, which is group II according to the World Health Organization anovulation classification and mostly consists of patients with polycystic ovary syndrome which affects 6-20% of women of reproductive age.
💡
Conclusion & Impact:Similarly, when inositol is used alone, it does not increase the pregnancy rate.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Anovulasyon · polikistik over sendromu · klomifen sitrat

Abstract

Infertility due to ovulation disorders is 25% of all infertility causes. The most common cause of ovulation disorders is patients with normogonadatropic normogonadism, which is group II according to the World Health Organization anovulation classification and mostly consists of patients with polycystic ovary syndrome which affects 6-20% of women of reproductive age. Oral ovulation induction agents are a suitable option only for patients in this group. The purpose of the ovulation induction is to stimulate the ovaries for monofollicular development. Oral agents used in ovulation induction can be divided into two groups, selective estrogen receptor modulators and aromatase inhibitors as first-line agents, and metformin and inositols as second-line agents. The aim of this review is to compare the use and efficacy of the primary oral ovulation induction agents, clomiphene citrate and letrozole, and also to reveal the contributions of the adjuvant drugs metformin and inositol. It is seen that letrozole is superior to clomiphene citrate in polycystic ovary syndrome and is currently preferred as the first-choice drug worldwide. Metformin alone increases the ovulation rate compared to placebo in women with polycystic ovary syndrome, but should not be used as first-line therapy for anovulation. Similarly, when inositol is used alone, it does not increase the pregnancy rate.

Özet

Ovulasyon bozukluklarına bağlı infertilite, tüm infertilite nedenlerinin %25'ini oluşturmaktadır. Ovulasyon bozukluklarının en sık nedeni, Dünya Sağlık Örgütü anovulasyon sınıflamasına göre grup II olan ve çoğunlukla üreme çağındaki kadınların %6-20'sini etkileyen polikistik over sendromlu hastalardan oluşan normogonadatropik normogonadizmli hastalardır. Oral ovulasyon indüksiyon ajanları sadece bu gruptaki hastalar için uygun bir seçenektir. Ovulasyon indüksiyonunun amacı, yumurtalıkları monofoliküler gelişim için uyarmaktır. Ovulasyon indüksiyonunda kullanılan oral ajanlar, birinci basamak ajanlar olarak selektif östrojen reseptör modülatörleri ve aromataz inhibitörleri ve ikinci basamak ajanlar olarak metformin ve inositoller olmak üzere iki gruba ayrılabilir. Bu derlemenin amacı, birincil oral ovulasyon indüksiyon ajanları olan klomifen sitrat ve letrozolün kullanım ve etkinliklerini karşılaştırmak ve ayrıca adjuvan ilaçlar olan metformin ve inositolün katkılarını ortaya koymaktır. Polikistik over sendromunda letrozolün klomifen sitrata göre daha üstün olduğu ve günümüzde dünya çapında ilk seçenek ilaç olarak tercih edildiği görülmektedir. Polikistik over sendromlu kadınlarda, tek başına metformin plaseboya kıyasla ovulasyon oranını arttırır, ancak anovulasyon için birinci basamak tedavi olarak kullanılmamalıdır. Benzer şekilde, inositol tek başına kullanıldığında gebelik oranını artırmamaktadır.

🔖

Cite This Article

NARİN, R. (2022). Oral Agents for Ovulation Induction. Düzce Tıp Fakültesi Dergisi, Cilt: 24 - Sayı: Special Issue, 90–96. https://ajindex.com/articles/657093

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. National Institute for Health and Care Excellence. Fertility: assessment and treatment for people with fertility problems. NICE clinical guideline 156; 2013.
  2. Crosignani PG, Bianchedi D, Riccaboni A, Vegetti W. Management of anovulatory infertility. Hum Reprod 1999;14(Suppl 1):108-19. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84.
  3. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. Ding DC, Chen W, Wang JH, Lin SZ. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: A population-based cohort study in Taiwan. Medicine (Baltimore). 2018;97(39):e12608. Zhang C, Ma J, Wang W, Sun Y, Sun K. Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome. Hum Reprod. 2018;33(11):2096-106.
  4. Norman RJ, Teede HJ. A new evidence-based guideline for assessment and management of polycystic ovary syndrome. Med J Aust. 2018;209(7):299-300.
  5. Ells LJ, Rees K, Brown T, Mead E, Al-Khudairy L, Azevedo L, et al. Interventions for treating children and adolescents with overweight and obesity: an overview of Cochrane reviews. Int J Obes (Lond). 2018;42(11):1823-33.
  6. Vegetti W, Guermandi E, Baroni E, Alagna F, Riccaboni A, Nicolosi AE, et al. [Induction of monofollicular cycles]. Minerva Ginecol. 2001;53(1):41-8.
  7. Italian. van Rumste MM, Custers IM, van der Veen F, van Wely M, Evers JL, Mol BW. The influence of the number of follicles on pregnancy rates in intrauterine insemination with ovarian stimulation: a meta-analysis. Hum Reprod Update. 2008;14(6):563-70. Nozaki M. [SERM]. Nihon Rinsho. 2006;64(9):1645-50.
  8. Japanese. Jie L, Li D, Yang C, Haiying Z. Tamoxifen versus clomiphene citrate for ovulation induction in infertile women. Eur J Obstet Gynecol Reprod Biol. 2018;228:57-64. de Paula Guedes Neto E, Savaris RF, von Eye Corleta H, de Moraes GS, do Amaral Cristovam R, Lessey BA. Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome. Fertil Steril. 2011;96(3):769-73.
  9. Glasier AF, Irvine DS, Wickings EJ, Hillier SG, Baird DT. A comparison of the effects on follicular development between clomiphene citrate, its two separate isomers and spontaneous cycles. Hum Reprod. 1989;4(3):252-6.
  10. Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Update